- Home
- EMN vs RYTM Comparison
EMN vs RYTM Comparison
Compare EMN & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | EMN | RYTM |
|---|---|---|
| Founded | 1920 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.0B | 6.4B |
| IPO Year | 1996 | 2017 |
Fundamental Metrics
Financial Performance| Metric | EMN | RYTM |
|---|---|---|
| Price | $75.27 | $95.04 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $78.57 | ★ $130.57 |
| AVG Volume (30 Days) | ★ 1.6M | 709.9K |
| Earning Date | 04-30-2026 | 05-25-2026 |
| Dividend Yield | ★ 4.45% | N/A |
| EPS Growth | N/A | ★ 28.34 |
| EPS | ★ 4.10 | N/A |
| Revenue | ★ $8,752,000,000.00 | N/A |
| Revenue This Year | $1.75 | $58.38 |
| Revenue Next Year | $3.32 | $83.95 |
| P/E Ratio | $18.41 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.11 | $45.91 |
| 52 Week High | $99.89 | $122.20 |
Technical Indicators
Market Signals| Indicator | EMN | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 51.02 | 40.60 |
| Support Level | $74.55 | $83.98 |
| Resistance Level | $82.30 | $96.92 |
| Average True Range (ATR) | 2.69 | 5.54 |
| MACD | -0.87 | -0.58 |
| Stochastic Oscillator | 31.61 | 37.85 |
Price Performance
Historical ComparisonAbout EMN Eastman Chemical Company
Established in 1920 to produce chemicals for Eastman Kodak, Eastman Chemical has grown into a global specialty chemical company with manufacturing sites around the world. The company generates the majority of its sales outside of the United States, with a strong presence in Asian markets. During the past several years, Eastman has sold noncore businesses, choosing to focus on higher-margin specialty product offerings.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.